文献速递胸部肿瘤

晚期非小细胞肺癌患者接受帕博利珠单抗治疗两年后的结局与后续治疗:法国全国队列研究

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.
PubMed 文献 · JAMA Oncol · 2026-01-01

该法国全国性回顾性队列研究纳入1480例接受帕博利珠单抗22-26个月后停药的晚期非小细胞肺癌患者,中位随访16个月,48个月OS率为76.9%,至后续治疗或死亡率为49.9%,仅26.1%患者接受后续治疗,免疫再挑战罕见(0.1%)。

要点

  • 完成2年帕博利珠单抗治疗的晚期NSCLC患者48个月OS率达76.9%。
  • 停药后仅26.1%接受后续治疗,免疫再挑战仅0.1%。
  • 后续治疗以化疗(51.7%)和放疗(47.3%)为主。

核心结论

  • 在接受帕博利珠单抗治疗的晚期非小细胞肺癌长期生存者中,生存结局较高,免疫再挑战不常见。

研究设计与样本

  • 法国全国性、基于人群的回顾性队列研究,使用法国国家健康保险数据库行政健康数据。
  • 感兴趣人群为1480例随访至少6个月的患者,中位(范围)年龄63.0(32.0-90.0)岁,女性537例(36.3%),男性943例(63.7%),616例(41.6%)接受帕博利珠单抗单药治疗。

主要发现

  • landmark后中位随访16个月(95%CI,15.2-16.8),48个月OS率为76.9%(95%CI,72.7%-81.3%)。
  • 帕博利珠单抗停药后48个月至后续治疗或死亡率为49.9%(95%CI,45.3%-55.0%)。
  • 387例(26.1%)接受后续治疗;停药后首次治疗为化疗200例(51.7%)、放疗183例(47.3%)、免疫治疗4例(1.0%)。
  • 所有后续治疗线中,19例(0.1%)接受免疫再挑战。

临床怎么用

  • 对于完成2年帕博利珠单抗治疗的晚期NSCLC患者,停药观察是合理策略,多数患者无需立即后续治疗。
  • 免疫再挑战在临床实践中极少使用,后续治疗以化疗和放疗为主。

局限性

  • 回顾性队列研究,使用行政健康数据,可能存在信息偏倚。
  • 仅纳入法国患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Two years of immunotherapy is the standard treatment for most patients with advanced non-small cell lung cancer. However, little is known about postimmunotherapy therapeutic strategies. OBJECTIVE: To describe subsequent treatments and outcomes after pembrolizumab discontinuation following 2 years of therapy. DESIGN, SETTING, AND PARTICIPANTS: This nationwide, population-based, retrospective cohort study used administrative health data from the French National Health Insurance database from patients who received a diagnosis of incident lung cancer between January 1, 2015, and December 31, 2022, who received pembrolizumab for 22 to 26 months and survived at least 29 months (landmark). The data cutoff was October 31, 2024. Data were analyzed in October 2025. EXPOSURE: Treatment with pembrolizumab for 22 to 26 months, followed by observation of subsequent therapeutic management after discontinuation. MAIN OUTCOMES AND MEASURES: Overall survival (OS) was defined as the time between landmark and death of any cause. Time to next treatment or death was defined as the time between the last pembrolizumab infusion and new treatment or death. RESULTS: Among 41 498 patients who received frontline pembrolizumab for advanced disease, 5293 were alive at the landmark time and completed 2 years of treatment, and 1555 discontinued pembrolizumab at 2 years. The population of interest for this study included 1480 patients with at least 6 months of follow-up; the median (range) age was 63.0 (32.0-90.0) years, 537 (36.3%) were female, 943 (63.7%) were male, and 616 (41.6%) had received pembrolizumab monotherapy. After a median follow-up of 16 months (95% CI, 15.2-16.8) after the landmark, the OS rate at 48 months was 76.9% (95% CI, 72.7%-81.3%), and the time to next treatment or death rate at 48 months after pembrolizumab discontinuation was 49.9% (95% CI, 45.3%-55.0%). Overall, 387 patients (26.1%) received subsequent therapy. The first treatments after pembrolizumab discontinuation were chemotherapy (200 [51.7%]), radiotherapy (183 [47.3%]), and immunotherapy (4 [1.0%]). Considering all subsequent treatment lines, 19 patients (0.1%) received an immunotherapy rechallenge. Twelve months after initiation of the new treatment, the OS rates were 87.0% (95% CI, 81.6%-92.7%) for radiotherapy, 69.9% (95% CI, 61.1%-80.0%) for chemotherapy, and 61.4% (95% CI, 41.3%-91.4%) for immunotherapy. CONCLUSIONS: This cohort study found that, among long-term cancer survivors with advanced non-small cell lung cancer who were treated with pembrolizumab, survival outcomes were high and immunotherapy rechallenge was uncommon.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Rousseau A, Foulon S, Planchard D, et al. Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab. JAMA Oncol. 2026. PMID: 41954917. doi:10.1001/jamaoncol.2026.0669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。